Our Company

Over the last 25 years, our research has focused on identifying molecular vulnerabilities in cancer cells that can be targeted with novel and innovative therapeutics.

This research led to the identification of novel drug targets that now form the basis of innovative strategies designed to significantly improve the current treatment options for cancer and improve the lives of patients and their families.

CV6 Therapeutics was founded in 2013 to accelerate the development of these novel targeted small molecule therapeutics. CV6 Therapeutics’ first oncology drug, CV6-168, has completed pre-clinical development and is entering a first-in-human clinical trial in 2023.